Introduction
Breast cancer is the most common cancer among females on all continents and the most rapidly increasing. [1] Early detection and advances in systemic therapy have improved clinical outcomes. [2] Women with both early breast cancer (EBC) and metastatic breast cancer (MBC) are surviving longer. [3] Many women in both populations have increased bone fragility either from treatment-induced bone loss or secondary to bony metastases. There already exists substantial data to support a role for bone-conserving therapy in patients with EBC to prevent treatment related bone loss. [4] [5] [6] [7] [8] [9] Despite improvements in long-term outcomes for early breast cancer, recurrence and death rates are still significant. Bone remains the most common site of breast cancer recurrence. The pivotal effects of the interaction between the tumor and its microenvironment have been recognized for more than 100 years through the so-called seed and soil hypothesis. [10] In advanced breast cancer, bone-modifying agents are important adjuncts to care in patients with metastatic bone disease. Skeletal-related complications of MBC include pathologic fractures, pain, spinal cord compression, and hypercalcemia of malignancy. One metastases occur in most women with advanced breast cancer. The destruction of bone in these lesions results from osteoclast-induced bone resorption that may be stimulated by osteoclast-activating factors released by tumor cells. [11, 12] Cytotoxic chemotherapy or hormone therapy is the preferred treatment for symptomatic bone disease, but progressive skeletal destruction ultimately leads to increased pain, immobility, and deterioration in the quality of life. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
Original Article comments and record dissent while voting for the consensus statements. Total of five broad question categories were part of the expert group discussions [ Tables 1-6 ].
Bone is the most frequent target of metastatic breast cancer, and although bone metastases are not life threatening, some of the complications (spinal cord compression, hypercalcemia) can be. [18] More important, bone metastases and their complications can be substantially disabling, require multiple interventions, and are costly to the patient and the health care system.
The bone microenvironment provides a supportive niche for cancer cell survival and tumor growth. [19, 20] Breast cancer cells have a natural predilection for metastasizing to the skeleton. Indeed, approximately 70% of patients with advanced breast cancer will develop bone metastases, and bone is the first site of metastasis in 30-40% of patients with relapsed disease. [21] The release of bone-derived growth factors and cytokines into the microenvironment can attract cancer cells to the bone surface and facilitate their growth and propagation. [22] In turn, many cancer cells secrete factors that can increase rates of bone resorption. [22] The dependence of metastasis on the link between cancer stem cells (the 'seeds') and the microenvironment (the 'soil') was first hypothesized by Stephen Paget more than a century ago, and this 'seed and soil' hypothesis has become especially meaningful to oncologists as our understanding of cancer-bone interactions has developed in recent years. [23] Indeed, the bone marrow is now also recognized as a sanctuary for harboring cancer 'seeds' for subsequent relapse in bone and other sites. [19, 20] Bisphosphonates (BPs) are the current standard of care for the prevention and treatment of malignant bone disease. [24, 25] BPs naturally bind to mineralized surfaces such as bone and inhibit osteoclast-mediated bone resorption. The second-generation nitrogen-containing BPs (N-BPs) (eg, zoledronic acid, pamidronate) have been proven more effective at reducing SREs compared with the first-generation BP compounds (eg, clodronate). [25] Ibandronate and zoledronic acid followed, with clinical trials demonstrating that the latter was significantly more effective than earlier generation bisphosphonates for control of bone metastases and reduction of skeletal-related events. [26, 27] Bisphosphonates were shown to be more effective and/or easier to use than previously existing agents (calcitonin, mithramycin) or newer agents with established activity (gallium nitrate). Over a short period of time, bisphosphonates became part of the standard of care for metastatic cancers, and clinical trials were initiated to determine their contribution to curative treatment of primary malignancies. It is clear that the addition of bisphosphonates to multidisciplinary treatment strategies has dramatically altered the clinical course of bone metastases.
Patients with EBC often develop bone loss secondary to cancer treatment itself, while in MBC metastases cause bone fragility and associated complications. Three mechanisms of bone loss due to cancer treatment have been identified. The first is as a result of estrogen deprivation therapies. Second, chemotherapies and supportive drugs, such as steroids, affect bone density directly or do so indirectly by the induction of premature ovarian failure.
Therapeutic ovarian ablation, whether medically or surgically induced, also results in premature menopause with consequent bone loss. In postmenopausal women there is on average a 2.6% loss of bone density in the first year of breast cancer treatment when treated with an aromatase inhibitor (AI). [28] In premenopausal women bone density loss averages 8% in the first year of treatment with premature ovarian suppression. [29] In contrast bone loss during natural menopause is typically 1% per year. [28] To date, no study has correlated bone loss in EBC with adverse clinical outcomes although indirect evidence shows that osteoporotic women with breast cancer have a higher incidence of fractures and mortality compared to age-matched controls. [30] Endocrine therapies may interfere with estrogen signaling (e.g. tamoxifen) or inhibit estrogen production (e.g. AIs); both of which may precipitate bone loss depending on a woman's menopausal status. Tamoxifen was the fi rst antiestrogen therapy used for treating breast cancer and is a mixed estrogen agonist/antagonist. [31] Tamoxifen effects on bone are dependent on the ambient estrogen concentrations; tamoxifen causes bone loss in premenopausal women, but is bone protective in postmenopausal women. [32] AIs, which have a role in treating postmenopausal women with breast cancer, cause bone resorption and a higher fracture risk compared to tamoxifen. [33, 34] However, since AIs significantly reduce the risk of breast cancer recurrence in postmenopausal women at five years compared to tamoxifen, and overall have a more favorable side effect profi le, AIs are preferred for adjuvant treatment among postmenopausal patients. Within the class, the impact of different AIs on bone density is still being studied. Recent data suggest that the steroidal AI exemestane may result in less BMD loss and potentially reduced fracture risk compared to the non-steroidal AIs, anastrozole and letrozole. [35] Cytotoxic chemotherapy is the only standard adjuvant treatment option for women with hormone receptor negative breast cancer and is also used in women with high-risk hormone receptor positive disease. hemotherapy treatment causes bone loss by directly damaging bone architecture or inducing early menopause in premenopausal women, and/or through concomitant steroid use. In MBC, tumor cells can affect bone by secreting growth factors that stimulate bone resorption. [36] Bone resorption releases factors that subsequently promote tumor growth and propagate a " vicious cycle " of tumor expansion and bone destruction. [36] Bone-modifying agents like BPs and denosumab have the potential to break this cycle and prevent bone loss. [37] 
Anticancer effects of bisphosphonates in breast cancer
The earliest clinical studies used oral clodronate to test the potential efficacy of bone modifying agents in preventing bone metastasis in early-stage (stages I-III) breast cancer. [36, 38, 39] Although clodronate is a relatively weak bisphosphonate compared with the intravenous BPs that were developed subsequently, [40] the effects of clodronate were sufficient to suggest that not only there was the potential to prevent bone metastases but that other effects on the disease course might be possible, thereby laying the groundwork for further clinical investigations. Subsequently, several large clinical trials have investigated the potential of adjuvant zoledronic acid to prevent recurrence of breast cancer. [8, 41, 42] Pilot and phase II studies in women with early-stage, highrisk breast cancer have reported that monthly zoledronic acid, in combination with standard anticancer therapy, can effectively increase DTC clearance and reduce DTC number and persistence in bone marrow compared with standard therapy alone. [43] [44] [45] These zoledronic acid-mediated reductions in DTC persistence might be one of the mechanisms underlying the observed clinical benefits in studies such as the Austrian Breast and Colorectal Study Group (ABCSG)-12 trial, [8] the ZOledronic acid and FemarA Synergy Trial (ZO-FAST), [46] and the Does Adjuvant Zoledronic acid redUce recurrence in stage II/III breast cancer? (AZURE) trial. [47] Bone-modifying agents for preventing disease recurrence
The seed and soil hypothesis provides a useful theoretical framework for evaluating breast cancer recurrence in women with early stage disease. The distribution of metastases does not appear to be random; rather, the soil of the bone microenvironment actually may promote cancer cell survival and tumor growth. Cancer cells often can be detected as disseminated tumor cells (DTCs) in the bone marrow or as circulating tumor cells (CTCs) in the blood of patients with breast cancer. Both DTCs and CTCs have been correlated with increased risks of disease recurrence and poor clinical outcomes. [46, 48] The DTCs in particular may seed future cancer recurrence in and outside bone, [49] and the specialized cellular interactions and signaling pathways in the bone marrow niche may inadvertently protect dormant DTCs from the cytotoxic and proapoptotic effects of systemic anticancer therapies. [19, 20] Bone remodeling is controlled by a variety of local and systemic factors, and is characterized by coupled and balanced osteolysis followed by osteogenesis. Tumor cells destroy the balance between osteoclastmediated bone resorption and the formation of new bone by osteoblasts. [22] As with all BPs, preferentially targets bone and is a key component of care for women with bone metastases from breast cancer. Zoledronic acid (in conjunction with standard anticancer therapy) is indicated for preventing skeletal-related events in patients with bone metastases from a variety of solid tumors and osteolytic lesions from multiple myeloma. [50] Moreover, zoledronic acid has been shown to not only prevent bone loss, [7, 42, 51, 52] but also to improve DFS and reduce DTC levels during adjuvant therapy for breast cancer. [53] [54] [55] [56] 
Conclusion
In conclusion, our experts recommended the routine use of Bone-modifying agent therapy for patients with breast cancer with evidence of bone metastases. Current standards of care for cancer bone pain management should be applied at the onset of pain, in concert with the initiation of bone modifying agent therapy. There is insufficient evidence to demonstrate greater efficacy of one bone-modifying agent over another. Experts also support the use of zoledronic acid as adjuvant therapy in unselected patients with early-stage breast cancer. Further investigation into the possible interaction between zoledronic acid and reproductive hormones is required. For postmenopausal women, the use of bisphosphonates remains appropriate for the prevention of treatment-induced bone loss and osteoporosis and might have beneficial effects on disease outcomes. The optimum schedule, duration, and type of bisphosphonate therapy remain unknown. Data for adjuvant denosumab look promising but are currently insufficient to make any recommendation. Nil.
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